Switzerland, particularly the regions of Basel, Zurich, and Lausanne, has emerged as a major European biotechnology hub for neurodegenerative disease research and drug development. This page provides an overview of Swiss biotech companies focused on Alzheimer's disease, Parkinson's disease, ALS, and related conditions.
The Swiss biotech ecosystem benefits from:
Location: Lausanne, Switzerland
Founded: 2003
Ticker: ACIU (NASDAQ)
Website: acimmune.com
AC Immune is a clinical-stage biopharmaceutical company focused on developing precision medicines for neurodegenerative diseases using its proprietary SupraAntigen and Morphomer technology platforms.
| Program | Indication | Mechanism | Stage | Partner |
|---|---|---|---|---|
| Semorinemab (ACI-35) | Alzheimer's disease | Anti-tau liposome vaccine | Phase 2 | Roche |
| ACI-35.164 | Alzheimer's disease | Phospho-tau vaccine | Phase 1b/2a | Proprietary |
| ACI-40 | Parkinson's disease | Alpha-synuclein vaccine | Phase 1 | Roche |
| ACI-89 | ALS | TDP-43 vaccine | Preclinical | Proprietary |
AC Immune's approach focuses on immunotherapy targeting misfolded proteins characteristic of neurodegenerative diseases. Their tau vaccine programs have shown promising results in clinical trials, and their partnership with Roche provides significant resources for clinical development[1].
Location: Lausanne, Switzerland
Founded: 2016
Website: asceneuron.com
Asceneuron is focused on developing small molecule therapeutics targeting tau pathology in Alzheimer's disease and other tauopathies.
| Program | Mechanism | Indication | Stage |
|---|---|---|---|
| ASN51 | Tau aggregation inhibitor | Alzheimer's disease | Phase 1/2 |
The company's lead program, ASN51, represents a differentiated approach to addressing tau pathology, which correlates strongly with cognitive decline in AD patients. Asceneuron's small molecule approach offers potential advantages over antibody-based therapies in terms of blood-brain barrier penetration[2].
Location: Zurich, Switzerland
Founded: 2007
Website: neurimmune.com
Neurimmune is a Swiss biotech company specializing in developing antibody-based therapeutics for neurodegenerative diseases using its proprietary Reverse Translational Medicine (RTM) platform.
Neurimmune's RTM platform identifies natural human antibodies from healthy elderly individuals with cognitive resilience, leveraging the body's natural defense mechanisms against protein aggregation diseases.
| Program | Indication | Mechanism | Stage | Partner |
|---|---|---|---|---|
| NI-202 (Aducanumab) | Alzheimer's disease | Anti-Aβ antibody | Approved | Biogen |
| NI-301 | Alzheimer's disease | Tau-targeting antibody | Phase 1 | — |
| NI-402 | Parkinson's disease | Anti-α-synuclein antibody | Preclinical | — |
| NI-501 | ALS | TDP-43 targeting | Discovery | — |
Neurimmune's most notable achievement is aducanumab ( Aduhelm), developed in partnership with Biogen and approved by the FDA for Alzheimer's disease treatment[3].
Location: Geneva, Switzerland
Founded: 2018
Website: vandria.com
Vandria develops novel therapeutics targeting mitochondrial function and cellular energetics in age-related diseases, including Alzheimer's and Parkinson's disease.
| Program | Mechanism | Indication | Stage |
|---|---|---|---|
| VNA-318 | Mitochondrial modulator | Alzheimer's disease | Phase 1 |
| VNA-100 | Mitochondrial modulator | Parkinson's disease | Preclinical |
The company's approach focuses on modulating mitochondrial quality control mechanisms—enhancing mitophagy, promoting mitochondrial biogenesis, and improving cellular energetics to protect neurons from degeneration[4].
Location: Lausanne, Switzerland
Founded: 2012
Website: mindmaze.com
MindMaze is a neurotechnology company developing digital therapeutics and brain-computer interfaces for neurorehabilitation.
While not a traditional drug development company, MindMaze represents an innovative approach to neurological care emerging from the Swiss biotech ecosystem[5].
| Institution | Location | Focus Areas |
|---|---|---|
| EPFL | Lausanne | Neuroscience, neuroengineering |
| University of Zurich | Zurich | Neurodegeneration, Alzheimer's research |
| University of Basel | Basel | Neuroscience, drug discovery |
| University of Geneva | Geneva | Mitochondrial biology |
The Swiss biotech companies frequently collaborate with:
Swiss neurodegeneration biotech companies have attracted significant investment:
Switzerland-based companies are actively conducting clinical trials:
The Swiss neurodegeneration biotech sector is positioned for continued growth: